TELA Bio Inc
NASDAQ:TELA
TELA Bio Inc
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 123 full-time employees. The company went IPO on 2019-11-08. The firm is focused on designing, developing and marketing tissue reinforcement materials for soft tissue reconstruction. The company offers a portfolio of products and solutions for care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. Its portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), is used for ventral hernia repair and abdominal wall reconstruction, inguinal hernia repair and hiatal hernia repair. Its OviTex PRS Reinforced Tissue Matrix (OviTex PRS) addresses needs in plastic and reconstructive surgery. Its OviTex PRS product is designed for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery. Its subsidiary include TELA Bio Limited.
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 123 full-time employees. The company went IPO on 2019-11-08. The firm is focused on designing, developing and marketing tissue reinforcement materials for soft tissue reconstruction. The company offers a portfolio of products and solutions for care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. Its portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), is used for ventral hernia repair and abdominal wall reconstruction, inguinal hernia repair and hiatal hernia repair. Its OviTex PRS Reinforced Tissue Matrix (OviTex PRS) addresses needs in plastic and reconstructive surgery. Its OviTex PRS product is designed for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery. Its subsidiary include TELA Bio Limited.
Revenue Record: TELA Bio reported Q3 2025 revenue of $20.7 million, up 9% year-over-year, marking its third consecutive quarter of sequential growth but below internal hopes.
Full-Year Guidance: Management expects at least 16% revenue growth for 2025 over 2024, with early expectations for at least 15% revenue growth in 2026.
Sales Force Expansion: The company reached its 2025 target of 76 territory managers and aims to reach 90+ in Q1 2026, with improved hiring speed and sales force productivity.
Financial Strength: Balance sheet was reinforced with a $20 million upsized debt facility and a $13 million equity offering, adding $26 million in net cash and ensuring a comfortable runway to profitability.
Operational Efficiency: Sales and marketing spend as a percentage of revenue declined significantly from 89.7% in Q1 to 73.6% in Q3, demonstrating improved expense management.
Commercial Momentum: Achieved over 100,000 global OviTex and OviTex PRS implantations and reported strong adoption and international traction, especially in Europe and the U.K.
Path to Profitability: Management reiterated breakeven is achievable at high $20 million in quarterly revenue, supported by operational leverage.
